Revenue: As of FY2026 Q2, the actual value is USD 1.5 M.

Financial Position

Aptevo Therapeutics Inc. reported cash and cash equivalents totaling $9.8 million as of June 30, 2026.

Capital Activities

During the second quarter of 2026, Aptevo Therapeutics Inc. raised $0.6 million under its Standby Equity Purchase Agreements (SEPAs) with Yorkville. The company also secured a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO451. Niowave made an at-the-market equity investment in Aptevo Therapeutics Inc. at closing, representing an initial 7.9% ownership position, with the potential to build up to 19.99%.

Operational Metrics (Clinical Development - Mipletamig)

In the Phase 1b/2 RAINIER trial for mipletamig, Aptevo Therapeutics Inc. demonstrated an 87% clinical benefit rate and an 81% remission rate across 31 evaluable unfit frontline AML patients. Among patients who achieved CR/CRi, 55% had blast reductions reaching the measurable residual disease-negative level (MRD neg). Additionally, 36% of patients with remissions had the TP53 genetic mutation. Six patients treated to date have proceeded to allogeneic stem cell transplant.

Outlook / Guidance

Aptevo Therapeutics Inc. anticipates completing dose optimization for mipletamig by year-end 2026 and expects a Phase 2 regulatory interaction in the first quarter of 2027. For APVO451, development candidate selection is targeted by year-end 2026, with IND-enabling studies planned for the first quarter of 2027. The company has also entered a ⁵⁰⁄₅₀ collaboration with Niowave to develop up to three radiopharmaceutical oncology programs, expanding its development strategy.